Le Lézard
Classified in: Health, Covid-19 virus
Subject: FDA

DetectaChem Receives FDA EUA Authorization for Mobile COVID-19 Detection Technology


SUGAR LAND, Texas, Sept. 3, 2020 /PRNewswire/ -- DetectaChem, the global leader in innovative portable threat detection technologies used daily by U.S. Homeland Security, Department of Defense and first responder agencies around the world, today announces their MobileDetect Bio (MD-Bio) BCC19 COVID-19 test kit has received FDA (Food and Drug Administration) EUA (Emergency Use Authorization).

The BCC19 test kit utilizes portable laboratory-grade diagnostic technology that can run up to 96 tests per device in just 30 minutes. The test detects nucleic acids from the 2019-nCoV virus to determine positive or negative results and then utilizes the free MobileDetect App for Apple and Android platforms to generate result reports with time, date, images, patient info, GPS mapping and more. Generated test reports can then be immediately sent via email or text to healthcare providers, laboratories or any other desired recipient. The BCC19 test kit achieved 100% positive and negative detection accuracy during FDA testing with comparable results and limits of detection to RT-PCR laboratory equipment.

Leveraging DetectaChem's experience in fully-integrated mobile solutions, the BCC19 test kit is also offered in a variety of Mobile Field Lab (MFL) configurations which contain up to 960 tests and all components needed for nasal or oral sampling and analysis in a single ruggedized and lightweight case. This unique option allows universities, schools, nursing homes, hospitals, police departments, emergency services and many others to deploy high-throughput mass testing solutions anytime, anywhere. As many testing sites can take 24 hours or much longer to produce test results, asymptomatic positive patients waiting for results can unknowingly infect countless others. With the BCC19 test kit's 30-minute cycle and diagnostic-level results, the window for spreading COVID-19 is drastically reduced from hours or days to minutes resulting in greater safety for organizations and their communities at large.  

"Accurate, fast, easy-to-use, and widely accessible testing is crucial in enabling a safe return to normal life for organizations and individuals around the world and we're proud to provide the MD-Bio BCC19 kit as a solution," said DetectaChem COO, Travis Kisner.

More information and ordering details can be found at www.MobileDetectBio.com.

Tweet this: Leader in #mobilefieldtesting detection @DetectaChem deploys new smartphone and tablet #COVID19test #Coronavirustest

About DetectaChem Inc.                                                          
DetectaChem is a Texas, USA-based privately-held company and manufacturer of rapidly deployable, handheld, intelligent, and easy-to-operate explosive, drug and bio detection systems deployed around the world. More information at www.DetectaChem.com

Press Contact:                                                                   
Jackie Lucas, Vera Voce Communication, LLC                 
+1-978-255-1159, [email protected]  

SOURCE DetectaChem


These press releases may also interest you

at 18:00
Voxtur Analytics Corp. , a North American technology company creating a more transparent and accessible real estate lending ecosystem, is pleased to announce that it has engaged the services of ICP Securities Inc. ("ICP") to provide automated market...

at 18:00
On April 19, 2024, the board of directors of Portland General Electric Company declared a quarterly common stock dividend of $0.50 per share, representing an increase of 5.3%, or $0.10 per share, on an annualized basis. The company's dividend is...

at 17:52
Adyton Resources Corporation  ("Adyton" or the "Company") announces it has closed its previously announced non-brokered private placement offering, pursuant to which it has issued 50,000,000 common shares of the Company ("Shares") at a price of...

at 17:20
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...

at 17:00
Lion Group Holding Ltd. ("Lion" or "the Company") , the operator of an all-in-one trading platform that offers a wide spectrum of products and services, today announced that on April 18, 2024, it received a delinquency notification letter from the...

at 16:30
Cosmos Health Inc. ("Cosmos Health" or the "Company'') , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor...



News published on and distributed by: